Advertisement
U.S. Markets closed

Nanobiotix S.A. (NANO.PA)

Paris - Paris Delayed Price. Currency in EUR
4.4800+0.0620 (+1.40%)
At close: 05:35PM CEST

Nanobiotix S.A.

60 rue de Wattignies
Paris 75012
France
33 1 40 26 04 70
https://www.nanobiotix.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 110

Key Executives

NameTitlePayExercisedYear Born
Mr. Laurent Levy Ph.D.Co-Founder, President of the Executive Board & CEO713.87kN/A1973
Mr. Bart Van RhijnChief Financial & Business Officer and Member of Executive Board628.49kN/A1973
Ms. Anne-Juliette Hermant M.A.Chief People Officer & Member of Executive Board354.9kN/A1974
Dr. Louis Kayitalire M.D.Chief Medical Officer500.8kN/A1958
Mr. Earl J. Bergey Ph.d.Co-FounderN/AN/A1955
Mr. Craig West CFASenior Vice President of Investor RelationsN/AN/AN/A
Mr. Brandon OwensVP of Strategic Marketing & Corporate CommunicationN/AN/AN/A
Ms. Margaret GalluzziVP & Global Head of Clinical OperationsN/AN/AN/A
Mr. Ventzislav Vassilev M.D.VP & Global Head of Safety VigilanceN/AN/AN/A
Dr. Leonard A. Farber M.D.Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Corporate Governance

Nanobiotix S.A.’s ISS Governance QualityScore as of October 1, 2024 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.